Examples of using Described in table in English and their translations into Slovenian
{-}
-
Financial
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Computer
-
Official/political
-
Programming
Dose modifications due to peripheral neuropathy are described in Table 1.
The steps and hypothesis described in table 6 of EN50388:2005 have to be defined by the applicant(column 3 not applicable), taking into consideration input data given in Annex D of the same standard;
Changes in selected laboratory parameters are described in Table 4.
The haircuts differ according to the residual maturity, type of interest payment( fixed or variable) and the valuation methodology applied by the national central bank( see Section 6.5),as described in Table 9.---.
A maximum of two consecutive dose reductions for each medicinal product, as described in Table 1, can be applied in case of toxicity.
The starting dose of methoxy polyethylene glycol- epoetin beta is based on the calculated previous weekly dose of darbepoetin alfa orepoetin at the time of substitution as described in Table 1.
The haircuts differ according to the residual maturity andcoupon structure of the debt instruments as described in Table 7 for eligible marketable fixed coupon and zero coupon debt instruments( 42).
Re-initiation of treatment should occur once the QTc decreases below 500 ms andat a lower dose as described in table 2.
Fishing in the Regulatory Area shall be restricted to anarea east of a line bound by the coordinates described in Table 3 and depicted in Figure 1(3) of the CEM referred to in point 8 of the Annex to this Regulation.
The EC verificationshall be performed in accordance with the module(s) described in Table 6.
The active substance in Recocam 20 mg/ml solution for injection for cattle,pigs and horses is an allowed substance as described in table 1 of the annex to Commission Regulation(EU) No 37/2010:.
Treatment should be withheld in patients who develop a QTc interval greater than 500 msec on at least 2 separate ECGs until the QTc interval is less than 481 msec or recovery to baseline if the QTc interval is greater than or equal to 481 msec,then resume TAGRISSO at a reduced dose as described in Table 1.
Changes in selected laboratory parameters are described in Table 4.
The haircuts differ according to the residual matu rity, type of interest payment( fixed or variable), the credit quality category and the valuation methodology applied by the NCB(see Section 6.5), as described in Table 9(*).
Post-hoc survival analyses were undertaken thereafter as described in table 7.
The starting dose of MIRCERA is based on the calculated previous weekly dose of darbepoetin alfa orepoetin at the time of substitution as described in Table 1.
Changes in selected laboratory values during therapy are described in Table 8.
The valuation haircuts applied to all marketable inverse floating rate debt instruments are thesame for all liquidity classes and are described in Table 8.
The verification documentation required for each scheme is described in Table 7.1.
The valuation haircuts applied to all marketable inverse floating rate debt instruments included in categories I to IV are thesame and are described in Table 8.
This table is intended to specify data to be collected in relation to the research surveys at sea that are described in Table 1G of this Annex.
( e) the third, fourth and fifth indents are replaced by the following:«--- The valuation haircuts applied to all marketable inverse floating rate debt instruments included in categories I to IVare the same and are described in Table 8.
The virologic response rates of the 41 subjects transplanted with HCV RNA<LLOQ is described in Table 17.
Adverse drug reactionsidentified during the post-marketing experience with Caelyx are described in Table 9.
The Commission notesthat this latter investment plan comprises part of the investments described in Tables 5-8.
Dose reductions are recommended for severe or persistent neutropenia andthrombocytopenia as described in Table 1:.
Dose adjustments in 100 mg steps per day(i.e. a 50 mg reduction per dosing)based on individual safety and tolerability are recommended as described in Table 1 and Table 2.
For multiple myeloma patients treated with Caelyx in combination with bortezomib who experience PPE or stomatitis,the Caelyx dose should be modified as described in Table 1 and 2 above respectively.
The haircuts are applied by deducting a certain percentage from the market value of the underlying asset. The haircuts applied to debt instruments included in categories I to IV differ according to the residual maturity andcoupon structure of the debt instruments as described in Table 7 for eligible marketable fixed coupon and zero coupon debt instruments.
( b) the third sentence of the second indent of the first paragraph is replaced by the following:« The haircuts applied to debt instruments included in categories I to IV differ according to the residual maturity andcoupon structure of the debt instruments as described in Table 7 for eligible marketable fixed coupon and zero coupon debt instruments(*).